Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

83 articles published Follow:
Deploying AI in Drug Discovery

Deploying AI in Drug Discovery: Moving Past the Hype

White Paper2 days ago55Views0Likes0Comments
Drug discovery is evolving rapidly, but successful AI adoption requires more than powerful models. It demands validated evidence, robust governance, and realistic expectations. MadeAi empowers life sciences teams to accelerate drug discovery with AI-powered evidence synthesis and expert human validation, delivering faster scientific insights while maintaining transparency, traceability, and regulatory-grade quality.  Download Deploying AI in…

Read More

AI for Patient-Reported Outcomes

How AI is Scaling Patient-Reported Outcomes into Structured, Submission-Ready Evidence

Blog2 days ago48Views0Likes0Comments
Scaling Patient-Reported Outcomes In the world of clinical research and drug development, patients’ own voices matter more than ever. Patient-reported outcomes (PROs) capture how people actually feel, their symptoms, quality of life, side effects, and daily functioning. Yet turning these often messy, free-text or survey responses into clean, structured data that regulators can trust has…

Read More

Ready Evidence Dossiers

How AI Helps HEOR Teams Build HTA-Ready Evidence Dossiers

BlogJuly 23, 202654Views0Likes0Comments
HTA-Ready Evidence Dossiers HTA (Health Technology Assessment)-ready evidence dossiers represent a critical deliverable for HEOR teams seeking market access and reimbursement for new therapies. These documents compile clinical, economic, and real-world evidence to meet strict requirements from health technology assessment bodies such as NICE, CADTH, or HAS. HTA-ready evidence dossiers demand more data, tighter timelines,…

Read More

SLR vs Meta Analysis

Systematic Literature Review vs. Meta-Analysis: Choosing the Right Approach

BlogJuly 8, 202695Views0Likes0Comments
SLR vs. Meta-Analysis: An Overview You've just received a research question from your stakeholders. They want to understand the effectiveness of a new therapeutic intervention across the published literature. Naturally, your next thought is: should we conduct a systematic literature review (SLR) or a meta-analysis? In healthcare and life sciences, this question sits at the…

Read More

Accelerating EU MDR Clinical Evaluation Reports Through AI-Assisted Systematic Literature Review

Accelerating EU MDR Clinical Evaluation Reports Through AI-Assisted Systematic Literature Review

Case StudyJune 30, 202650Views0Likes0Comments
How do you prepare Clinical Evaluation Reports (CERs) without spending months reviewing clinical literature? In this case study, MadeAi partnered with a medical device manufacturer to conduct systematic literature reviews supporting Clinical Evaluation Reports (CERs) for three vascular devices. Using AI-assisted search, explainable screening, structured data extraction, and SME validation, the team generated submission-ready clinical…

Read More